PROCEPT BioRobotics Corporation PRCT
20.62 USD +0.35 (+1.73%)
At closeNov 6, 2026, 4:00 PM EST
20.57 -0.05 -0.24%
After hours · Nov 6, 4:00 PM ET
19.41 Day range 20.80
16.67 52-week range 38.11
- YTD
- -34.46%
- 1 year
- -34.12%
News
benzinga.com Truist Securities Maintains Hold on PROCEPT BioRobotics, Raises Price Target to $24 Truist Securities analyst Richard Newitter maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Hold and raises the price target from $21 to $24.
benzinga.com UBS Maintains Neutral on PROCEPT BioRobotics, Raises Price Target to $21 UBS analyst Patrick Wood maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Neutral and raises the price target from $20 to $21.
benzinga.com Leerink Partners Maintains Market Perform on PROCEPT BioRobotics, Raises Price Target to $22 Leerink Partners analyst Mike Kratky maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Market Perform and raises the price target from $20 to $22.
marketbeat.com PROCEPT BioRobotics Q3 Earnings Call Highlights PROCEPT BioRobotics NASDAQ: PRCT reported 18% revenue growth in the third quarter of 2026 as demand for its HYDROS systems and procedure-related products helped offset slower-than-expected placements…
seekingalpha.com PROCEPT BioRobotics Corporation (PRCT) Q3 2026 Earnings Call Transcript PROCEPT BioRobotics Corporation (PRCT) Q3 2026 Earnings Call Transcript
zacks.com PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Lags Revenue Estimates PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.38 per share a year ago.
benzinga.com PROCEPT BioRobotics Q3 2026 Earnings Call Transcript PROCEPT BioRobotics (NASDAQ:PRCT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com PROCEPT BioRobotics Affirms FY2026 Sales Guidance of $390.000M-$410.000M vs $395.409M Est PROCEPT BioRobotics (NASDAQ:PRCT) affirms FY2026 sales outlook from $390.000 million-$410.000 million to $390.000 million-$410.000 million vs $395.409 million estimate.
globenewswire.com PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance SAN JOSE, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing…